Biotechnology News

SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H...

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support...

HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion...

TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief...

Eascra Biotech, a nanomedicine startup, with a lab in Worcester, Massachusetts, has appointed Dr. Andrew Goodearl, Ph.D., as Chief Scientific Officer.

Eascra Biotech has been awarded a NASA In Space Production Applications (InSPA) Phase 2 contract, valued at $7.96 million.

REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

REYKJAVÍK (27. ágúst 2026) — Alvotech (NASDAQ: ALVO, ALVO SDB) tekur þátt í tveimur fjárfestaráðstefnum í Bandaríkjunum í næsta mánuði þar sem Róbert Wessman, stofnandi og starfandi stjórnarformaður,...

REYKJAVIK, Iceland, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...